loading...| Preferred Name |
Maribavir |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C82254 |
| Accepted_Therapeutic_Use_For |
Treatment of Adults and Pediatric Patients with Post-Transplant CMV Infection/Disease. |
| ALT_DEFINITION |
A substance that blocks the ability of viruses to make new viruses and infect cells. It is being studied in the prevention of cytomegalovirus infection in cancer patients who have had a donor stem cell transplant. It is a type of antiviral agent. |
| CAS_Registry |
176161-24-3 |
| Chemical_Formula |
C15H19Cl2N3O4 |
| code |
C82254 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
An orally available benzimidazole riboside compound with activity against cytomegalovirus (CMV). Maribavir is a selective ATP competitor of viral UL97 kinase, which is involved in viral nuclear maturation events, such as viral DNA assembly and movement of viral capsids from the nucleus of infected cells. Maribavir has activity against strains of CMV that are resistant to standard anti-CMV agents. |
| Display_Name |
Maribavir |
| FDA_UNII_Code |
PTB4X93HE1 |
| FULL_SYN |
NTBC maribavir MARIBAVIR BW 1263W94 Maribavir LIVTENCITY Benzimidazol-2-amine |
| label |
Maribavir |
| Legacy Concept Name |
Maribavir |
| NCI_Drug_Dictionary_ID |
429563 |
| PDQ_Closed_Trial_Search_ID |
429563 |
| PDQ_Open_Trial_Search_ID |
429563 |
| Preferred_Name |
Maribavir |
| prefixIRI |
Thesaurus:C82254 |
| prefLabel |
Maribavir |
| Semantic_Type |
Pharmacologic Substance |
| UMLS_CUI |
C1508759 |
| subClassOf |